{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T13:32:12Z","timestamp":1794317532236,"version":"4.9.0"},"reference-count":31,"publisher":"Cambridge University Press (CUP)","issue":"5","license":[{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"unspecified","delay-in-days":55,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Spectr."],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec id=\"S1092852924000531_sec1\"><jats:title>Objective<\/jats:title><jats:p>Many psychotropic drugs are highly associated with related weight gain. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are established anti-obesity and glucose-lowering agents. Preliminary evidence also indicates they are fit for purpose in mitigating psychotropic drug-related weight gain (PDWG). This systematic review aims to synthesize the extant evidence from randomized controlled trials (RCTs) on the effects of GLP-1RAs on weight change in persons experiencing PDWG.<\/jats:p><\/jats:sec><jats:sec id=\"S1092852924000531_sec2\" sec-type=\"methods\"><jats:title>Methods<\/jats:title><jats:p>Online databases (ie, PubMed, OVID Medline, Google Scholar) were searched to identify relevant studies from inception to January 1, 2024. Articles were screened by title, abstract, and full-text by three independent reviewers against inclusion and exclusion criteria.<\/jats:p><\/jats:sec><jats:sec id=\"S1092852924000531_sec3\" sec-type=\"results\"><jats:title>Results<\/jats:title><jats:p>We identified six studies with participants aged \u226518 (n=374) that were eligible for inclusion in our systematic review. Most studies reported a significant and clinically meaningful effect of GLP-1RAs on anthropometrics and\/or metabolics. All RCTs replicated the finding of modest or greater effects of GLP-1RAs; the most studied agents were liraglutide and exenatide. There was insufficient literature to conduct a meta-analysis.<\/jats:p><\/jats:sec><jats:sec id=\"S1092852924000531_sec4\" sec-type=\"conclusions\"><jats:title>Conclusion<\/jats:title><jats:p>Evidence suggests that GLP-1RAs are effective in mitigating weight gain in persons prescribed psychiatric medication. It is hypothesized that GLP-1RAs may moderate weight change in persons prescribed psychiatric medication through direct effects on metabolism and cognitive processes implicated in hunger\/satiety. Future studies should aim to explore the long-term safety, tolerability, and efficacy profiles of various GLP-1RAs in the treatment and prevention of abnormal weight and metabolic homeostasis in psychiatric populations.<\/jats:p><\/jats:sec>","DOI":"10.1017\/s1092852924000531","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T06:08:19Z","timestamp":1732514899000},"page":"347-353","source":"Crossref","is-referenced-by-count":14,"title":["A systematic review on the efficacy of GLP-1 receptor agonists in mitigating psychotropic drug-related weight gain"],"prefix":"10.1017","volume":"29","author":[{"given":"Trisha","family":"Menon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serene","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan Yi","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gia Han","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela T.H.","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla M.","family":"Teopiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5963-2676","authenticated-orcid":false,"given":"Bing","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taeho Greg","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Jing Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Valentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangguang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maj","family":"Vinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2551-5230","authenticated-orcid":false,"given":"Heidi K.Y.","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4733-2523","authenticated-orcid":false,"given":"Roger S.","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2024,11,25]]},"reference":[{"key":"S1092852924000531_r25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312323"},{"key":"S1092852924000531_r28","unstructured":"[28] EMA statement on ongoing review of GLP-1 receptor agonists. European Medicines Agency. 2024. https:\/\/www.ema.europa.eu\/en\/news\/ema-statement-ongoing-review-glp-1-receptor-agonists."},{"key":"S1092852924000531_r14","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2019.09.010"},{"key":"S1092852924000531_r12","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.156.11.1686"},{"key":"S1092852924000531_r13","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2019.09.003"},{"key":"S1092852924000531_r22","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14334"},{"key":"S1092852924000531_r18","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2020.113670"},{"key":"S1092852924000531_r27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2023.05.041"},{"key":"S1092852924000531_r16","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1085799"},{"key":"S1092852924000531_r19","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13167"},{"key":"S1092852924000531_r10","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.24com15322"},{"key":"S1092852924000531_r8","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.1.112"},{"key":"S1092852924000531_r7","doi-asserted-by":"publisher","DOI":"10.1177\/070674371205700103"},{"key":"S1092852924000531_r15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d7771"},{"key":"S1092852924000531_r26","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30173-3"},{"key":"S1092852924000531_r1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20230922"},{"key":"S1092852924000531_r2","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(19)30416-X"},{"key":"S1092852924000531_r29","unstructured":"[29] Update on FDA\u2019s ongoing evaluation of GLP-1 Ras and Suicidality. U.S. Food and Drug Administration. FDA Center for Drug Evaluation and Research. 2024. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/update-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type#:~:text=Similarly%2C%20our%20reviews%20of%20the,of%20suicidal%20thoughts%20or%20actions."},{"key":"S1092852924000531_r31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2024.10.062"},{"key":"S1092852924000531_r4","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852922001043"},{"key":"S1092852924000531_r5","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20230012"},{"key":"S1092852924000531_r6","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-012-0313-8"},{"key":"S1092852924000531_r30","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2295397"},{"key":"S1092852924000531_r24","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2024.2335215"},{"key":"S1092852924000531_r17","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12795"},{"key":"S1092852924000531_r9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0148871"},{"key":"S1092852924000531_r23","first-page":"14898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"The BMJ"},{"key":"S1092852924000531_r21","first-page":"89","article-title":"Liraglutide in obese or overweight individuals with stable bipolar disorder","volume":"44","author":"McElroy","year":"2024","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"S1092852924000531_r11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214530"},{"key":"S1092852924000531_r3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2021.12.110"},{"key":"S1092852924000531_r20","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.1220"}],"container-title":["CNS Spectrums"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1092852924000531","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T04:22:08Z","timestamp":1736482928000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1092852924000531\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1092852924000531"],"URL":"https:\/\/doi.org\/10.1017\/s1092852924000531","relation":{},"ISSN":["1092-8529","2165-6509"],"issn-type":[{"value":"1092-8529","type":"print"},{"value":"2165-6509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10]]}}}